Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tissue biomarkers in melanoma patients treated with TIL.

PloS one - 1 Jan 2012

Knol Anne-Chantal, Nguyen Jean-Michel, Pandolfino Marie-Christine, Quéreux Gaëlle, Brocard Anabelle, Peuvrel Lucie, Saint-Jean Mélanie, Saiagh Soraya, Khammari Amir, Dréno Brigitte

Abstract excerpt

While treating stage III melanoma patients with autologous therapeutic TIL in an adjuvant setting, we previously reported a significant benefit of treatment on both progression-free survival and overall survival in patients with only one invaded lymph node (early stage III) compared to patients with more than one invaded lymph nodes (advanced stage III). In this context, in order to understand the difference of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Count
Share to Cytokines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Lymphatic Metastasis

Share to Lymphocytes, Tumor-Infiltrating

Share to Melanoma

Share to Neoplasm Staging

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 23284620
DOI: 10.1371/journal.pone.0048729
PMCID: PMC3527474

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tissue biomarkers in melanoma patients treated with TIL.PMID 23284620Read ↗

Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival.Semantic proximity Read ↗

Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignanciesSemantic proximity Read ↗

Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.Semantic proximity Read ↗

Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.Semantic proximity Read ↗

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Semantic proximity Read ↗

Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.Semantic proximity Read ↗

Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanomaSemantic proximity Read ↗

Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations.Semantic proximity Read ↗

Tumour-infiltrating lymphocytes in primary melanoma: functional consequences of differential IL-2 receptor expression.Semantic proximity Read ↗

Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients.Semantic proximity Read ↗

Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.Semantic proximity Read ↗

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.